摘要
目的探讨泽桂癃爽胶囊联合左氧氟沙星治疗慢性前列腺炎的临床疗效。方法选用回顾性病例对照研究方法,分析2021年2月—2023年11月首都医科大学附属北京友谊医院平谷医院收治的84例慢性前列腺炎患者的病例资料,按治疗方案不同分为对照组和治疗组,每组各42例。对照组口服左氧氟沙星片,0.5 g/次,1次/d。治疗组在对照组治疗基础上口服泽桂癃爽胶囊,2粒/次,1次/d。两组疗程28 d。观察两组的临床疗效,比较两组治疗前后临床表现评分、美国国立卫生研究院慢性前列腺炎症状积分指数(NIH-CPSI)评分、症状自评量表(SCL-90)评分及前列腺按摩液(EPS)中白细胞(WBC)和卵磷脂小体(SPL)水平。结果治疗后,治疗组总有效率是95.24%,显著高于对照组的80.95%(P<0.05)。治疗后,两组小便频急评分、尿后余沥不尽评分、尿道灼热评分、会阴疼痛或不适评分、少腹疼痛或不适评分、腰骶部疼痛或不适评分均较同组治疗前显著降低(P<0.05);治疗后,治疗组临床表现评分均低于对照组(P<0.05)。治疗后,两组NIHCPSI、SCL-90评分均显著降低(P<0.05);治疗后,治疗组NIH-CPSI、SCL-90评分均显著低于对照组(P<0.05)。治疗后,两组EPS中WBC显著降低,而EPS中SPL水平均显著增加(P<0.05);治疗后,治疗组EPS中WBC和SPL水平改善优于对照组(P<0.05)。结论泽桂癃爽胶囊联合左氧氟沙星治疗慢性前列腺炎具有较好的临床疗效,能有效抑制前列腺炎症,促进患者临床表现减轻及身心健康状态改善,值得推广应用。
Objective To explore the clinical efficacy of Zegui Longshuang Capsules combined with levofloxacin in treatment of chronic prostatitis.Methods A retrospective case-control study was used to analyze the case data of 84 patients with chronic prostatitis admitted to Pinggu Hospital,Beijing Friendship Hospital Affiliated to Capital Medical University from February 2021 to November 2023.They were divided into control and treatment groups according to different treatment plans,and each group had 42 cases.Patients in the control group were po administered with Levofloxacin Tablets,0.5 g/time,once daily.Patients in the treatment group were po administered with Zegui Longshuang Capsules on the basis of the control group,2 grains/time,once daily.Two groups were treated for 28 d.The clinical efficacy of two groups was compared,and the clinical manifestation score,National Institutes of Health Chronic Prostatitis Syndrome Score(NIH-CPSI)score,Symptom Self-rating Scale(SCL-90)score and the levels of white blood cells(WBC)and lecitin bodies(SPL)in prostate massage fluid(EPS)were compared between the two groups before and after treatment.Results After treatment,the total effective rate of the treatment group was 95.24%,which was significantly higher than that of the control group(80.95%,P<0.05).After treatment,the scores of rapid urination,incomplete urination,urethral burning,perineal pain or discomfort,low abdominal pain or discomfort,lumbosacral pain or discomfort were significantly lower in 2 groups than before treatment(P<0.05).After treatment,the clinical performance score of the treatment group was lower than that of the control group(P<0.05).After treatment,NIH-CPSI and SCL-90 scores were significantly decreased in both groups(P<0.05).After treatment,NIH-CPSI and SCL-90 scores in the treatment group were significantly lower than those in the control group(P<0.05).After treatment,WBC in EPS was significantly decreased,but SPL level in EPS was significantly increased in both groups(P<0.05).After treatment,WBC and SPL leve
作者
邢劲
曲直
陈垒
杨立军
XING Jin;QU Zhi;CHEN Lei;YANG Lijun(Department of Urology,Pinggu Hospital,Beijing Friendship Hospital Affiliated to Capital Medical University,Beijing 101200,China)
出处
《现代药物与临床》
CAS
2024年第10期2635-2639,共5页
Drugs & Clinic
